Covid 19 Research using Clinical Trials (Home Page)
HP:0006516: Hypersensitivity pneumonitisHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug668 | Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument Wiki | 1.00 |
| drug376 | Baricitinib Wiki | 0.38 |
Correlated MeSH Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000542 | Alveolitis, Extrinsic Allergic NIH | 1.00 |
| D006967 | Hypersensitivity, NIH | 0.45 |
| D017563 | Lung Diseases, Interstitial NIH | 0.29 |
| D008171 | Lung Diseases, NIH | 0.24 |
| D011014 | Pneumonia NIH | 0.06 |
Correlated HPO Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012393 | Allergy HPO | 0.45 |
| HP:0006515 | Interstitial pneumonitis HPO | 0.29 |
| HP:0002088 | Abnormal lung morphology HPO | 0.24 |
| HP:0002090 | Pneumonia HPO | 0.06 |
There is one clinical trial.
Clinical Trials
1 Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis
The objective of this study is to administer and validate a disease specific health related quality of life (HRQOL) survey for patients with Chronic Hypersensitivity Pneumonitis (CHP).
NCT04273867 Hypersensitivity Pneumonitis Chronic Hypersensitivity Pneumonitis Interstitial Lung Disease Extrinsic Allergic Alveolitis Health-related Quality of Life Other: Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument MeSH:Lung Diseases Lung Diseases, Interstitial Pneumonia Alveolitis, Extrinsic Allergic Hypersensitivity
HPO:Abnormal lung morphology Allergy Hypersensitivity pneumonitis Interstitial pneumonitis Interstitial pulmonary abnormality Pneumonia
Primary Outcomes
Description: The newly developed survey that is being validated consists of 42 items that assess the impact that Hypersensitivity Pneumonitis has on daily life for those who have the disease.
Measure: Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis Time: Day 0
Description: This survey will be used to assess the validity of the newly developed health-related quality of life instrument. This survey consists of 12 items. The average score for this survey has been calibrated to 50 with scores below 50 indicating a below average score and scores above 50 indicating an above average score.
Measure: Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis by administering the Short Form (SF-12) Survey Time: Day 0
Description: This survey will be used to assess the validity of the newly developed health-related quality of life instrument. This survey consists of 15 items and is scored from 0-100 with 100 indicating good health.
Measure: Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis by administering the King's Brief Interstitial Lung Disease Questionnaire Time: Day 0
Description: The newly developed survey will be administered again in 2 weeks following the first assessment.
Measure: Change in Health-related Quality of Life Assessment Score Time: 2 weeks following Day 0
HPO Nodes
Primary Outcomes
Description: The newly developed survey that is being validated consists of 42 items that assess the impact that Hypersensitivity Pneumonitis has on daily life for those who have the disease.
Measure: Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis Time: Day 0Description: This survey will be used to assess the validity of the newly developed health-related quality of life instrument. This survey consists of 12 items. The average score for this survey has been calibrated to 50 with scores below 50 indicating a below average score and scores above 50 indicating an above average score.
Measure: Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis by administering the Short Form (SF-12) Survey Time: Day 0Description: This survey will be used to assess the validity of the newly developed health-related quality of life instrument. This survey consists of 15 items and is scored from 0-100 with 100 indicating good health.
Measure: Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis by administering the King's Brief Interstitial Lung Disease Questionnaire Time: Day 0Description: The newly developed survey will be administered again in 2 weeks following the first assessment.
Measure: Change in Health-related Quality of Life Assessment Score Time: 2 weeks following Day 0